Experimental and epidemiological evidence suggest that dysregulation of proteins involved in iron metabolism plays a critical role in cancer. The mechanisms by which cancer cells alter homeostatic iron regulation are just beginning to be understood. Here we demonstrate that iron regulatory protein 2 (IRP2) plays a key role in iron accumulation in breast cancer. Although both IRP1 and IRP2 are over-expressed in breast cancer, the overexpression of IRP2, but not IRP1, is associated with decreased ferritin H and increased transferrin receptor 1 (TfR1). Knock-down of 
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Experimental and epidemiological evidence suggest that dysregulation of proteins involved in iron metabolism plays a critical role in cancer. The mechanisms by which cancer cells alter homeostatic iron regulation are just beginning to be understood. Here we demonstrate that iron regulatory protein 2 (IRP2) plays a key role in iron accumulation in breast cancer. Although both IRP1 and IRP2 are over-expressed in breast cancer, the overexpression of IRP2, but not IRP1, is associated with decreased ferritin H and increased transferrin receptor 1 (TfR1). Knock-down of IRP2 in triple negative MDA-MB-231 human breast cancer cells increases ferritin H expression and decreases TfR1 expression, resulting in a decrease in the labile iron pool. Further, IRP2
knockdown reduces growth of MDA-MB-231 cells in the mouse mammary fat pad. Gene expression microarray profiles of breast cancer patients demonstrate that increased IRP2 expression is associated with high grade cancer. Increased IRP2 expression is observed in luminal A, luminal B and basal breast cancer subtypes, but not in breast tumors of the ERBB2 molecular subtype. These results suggest that dysregulation of IRP2 is an early nodal point underlying altered iron metabolism in breast cancer and may contribute to poor outcome of some breast cancer patients.
Introduction
Iron is essential for normal cell growth and proliferation. A growing body of evidence suggests that iron dysregulation plays a role in the pathogenesis and progression of many common diseases, including cancer (1-3). The underlying mechanisms by which iron contributes to malignancy are incompletely understood, and include the production of reactive oxygen species (ROS); induction of oxidative-responsive transcription factors (AP-1, NFκB) (4, 5) ; stimulation of oncogenic pathways (6) ; and effects on DNA synthesis (7), DNA repair (8) and the cell cycle (9) (10) (11) . Breast and other cancers are characterized by an increase in iron uptake and/or reduction in iron efflux, both of which favor iron sequestration (12) . Iron deprivation has demonstrated inhibition of tumor growth and has been used to treat cancers in animal models and human clinical trials with some success (13) (14) (15) (16) (17) (18) .
There is a particularly close association between iron and breast cancer. Lifetime exposure to estrogen is a risk factor for breast cancer (19) . Estrogen contributes to tumor formation in part by redox cycling, which promotes the formation of oxidized DNA bases (20) . This DNAdamaging effect of estrogen is potentiated by iron (21, 22) . In addition, estrogen and iron exert combined effects in stimulating proliferation of breast cancer cells in tissue culture (23) , suggesting that iron may play both a tumor initiating and tumor promoting role in breast cancer.
ferroportin (SLC40A1), in breast cancers contributes to the breast cancer phenotype (12) , and the combined expression of low ferroportin and high hepcidin (HAMP)(export dyad) predict poor outcome in breast cancer patients after definitive surgery. Breast cancers that express high transferrin receptor 1 and low HFE (the hemochromatosis gene, a negative regulator of TfR1[TFRC]), and are thus predicted to exhibit high iron uptake, are also associated with poor outcome (25) .
What mechanisms underlie the altered expression of proteins that regulate iron import and efflux in breast cancer? Because iron regulatory proteins (IRPs), IRP1 (ACO1) and IRP2 (IREB2), play a central role in the regulation of intracellular iron metabolism (26) , we examined the role of IRP1 and IRP2 in breast cancer. IRPs regulate iron by binding to IREs, iron responsive elements present in the untranslated region of mRNAs encoding iron-related proteins, such as ferritin H (FTH1) (27, 28) , ferritin L (FTL) (29) , transferrin receptor 1(TfR1) (30, 31) , and ferroportin (32) .
The role of IREs in ferritin and TfR1 have been particularly well studied (26) . When IRPs bind to the IRE in the 5'-UTR of ferritin, they inhibit translation. When IRPs bind to the IREs in the 3'-UTR of TfR1, they stabilize the mRNA. Because decreased ferritin decreases iron storage, whereas increased TfR1 increases iron uptake, enhanced binding of IRPs to IRE leads to increased metabolically available iron (the labile iron pool).
In this study, we report that IRP2 plays a predominant role in regulation of proteins of iron metabolism in breast cells and is overexpressed in breast cancer cells. Knockdown of IRP2 retards breast tumor growth in vivo. Further, high IRP2 expression is associated with high tumor grade and breast cancer molecular subtypes. These results demonstrate that IRP2 plays an important role in breast cancer by enhancing iron accumulation in tumor cells.
Materials and Methods
Chemicals and cell cultures-Human mammary epithelial cells (HME) cells were purchased from Lonza and used at less than passage 10. R5 cells were a kind gift from R. Weinberg (12, 33) . R5 cells are tumor-forming variants of HME cells established by sequential transformation of HME cells with telomerase catalytic subunit, SV40 T antigen, and oncogenic H-ras. HME and R5 cells were maintained in the same medium (DMEM-F12 supplemented with L-glutamine, insulin, human epidermal growth factor, and hydrocortisone) for 24 hours before harvest. Cell proliferation assay -Cell proliferation was measured using a WST-1 assay kit following the manufacture's instruction (Roche Applied Science). Apoptosis assays -The luminescent-based Caspase-Glo 3/7 assay kit (Promega) was used according to the manufacturer's instructions. Annexin V and 7-AAD permeability were analyzed using an apoptotic detection kit (BD Bioscience), a MACSQuant Analyzer (Miltenyi Biotec), and FlowJo software (Treestar).
DNA construction and lentivirus infection -
The target sequences for gene silencing of IRP1 and IRP2 are: IRP2-shRNA-1(GATCTTACAGTTGACCATTCT), IRP2-shRNA-2(GGAGTGGCTGGAAAGTTTGTT), IRP1-shRNA-1(GTAATAGCATATGCAATTGCT), IRP1-shRNA-2(GAACGATACACTATCATTATT). The shRNA cassettes were cloned into the lentiviral vector plu-EGFP as previously described (34, 35) . For IRP2 rescue experiment, a PCRbased mutagenesis method was used and IRP2 shRNA-2 targeting sequence in IRP2 expression vector was converted from GGAGTGGCTGGAAAGTTTGTT to GGAGTGGCaGGtAAaTTcGTc (lower case indicating mutation site). The detailed procedure of virus collection and infection has been previously described (34) .
Establishment of inducible IRP2 knockdown clones -Tet-inducible IRP2 knockdown clones were established in MDA-MB-231-Luc cells by lentiviral transduction of pLenti6/TR (Invitrogen) and blastidin (10 µg/ml) selection followed by introduction of a lentiviral vector containing an IRP2
shRNA sequence under the control of TRE and selection with puromycin (0.8 µg/ml). The shRNA sequence used to knockdown IRP2 was described previously (36) .
Labile iron pool assay-The cellular labile iron pool was measured using calcein as a fluorescent probe, essentially as previously described (12 Clonogenic assay -After infection with shRNA expressing lentivirus, cells were seeded in 6-well plates at 600, 400, and 200 cells per well. 20 days later, cells were fixed in 10% formalin and stained with 0.25% crystal violet to detect colony formation.
Real-time RT-PCR-Real-time PCR was performed on the ABI Prism 7000 sequence detection system (Applied Biosystems, Foster City, CA) as described previously (36) . PCR Primers were designed with IDT PrimerQuest software (Integrated DNA Technologies, Inc.), and are listed in Supplemental Table 1 .
Western blotting-Western blotting was performed as described previously (37) . Whole cellular protein was extracted using NP-40 lysis buffer containing a protease inhibitor cocktail (Roche Diagnostics). Antibodies used for detection were glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (Fitzgerald), TfR1(Invitrogen), ferritin H(38), IRP1 (MediMabs) and IRP2 (Santa Cruz).
RNA bandshift assay-RNA bandshift assays were performed as previously described (36) calipers; bioluminescent imaging was performed once weekly from day 11 to day 32 postinoculation. Mice were removed from the study when tumor volume reached 10% of total body weight, and the study was terminated at day 102.
Statistical analysis. Survival times were compared using Kaplan-Meier curves and Log-Rank tests. Tumor volumes and luciferase (flux) values were compared using a repeated measures model taking into account the multiple measurements on each animal. All analyses were performed using SAS version 9.3. Significance levels were set at 0.0167 to allow for 3 pair-wise comparisons to be made among the 3 treatment groups (IRP2KD1, IRP2KD2 and control). As shown in Figure 1A , TfR1 is increased, while ferritin H is reduced in breast cancer cell lines (R5 and MCF7) when compared to their non-malignant counterparts (HME and MCF10A), consistent with an iron sequestration phenotype in cancer cells.
Gene expression analysis in breast tumors-

IRP2 is consistently increased in breast cancer cells. Since both ferritin H and TfR1 are
controlled by the IRP-IRE system, we tested whether altered expression of either IRP1 or IRP2 was responsible for the change in ferritin and TfR1 observed in breast cancer cells. As shown in Figure 1B , IRP2 mRNA was increased 2-fold in R5 and 4-fold in MCF-7 cells compared to their non-malignant counterparts, HME and MCF10A, while IRP1 mRNA levels were unchanged.
Western blots were performed to assess IRP1 and IRP2 protein levels. In contrast to what was observed at the mRNA level, both IRP1 and IRP2 protein levels were increased in R5 and MCF7 breast cancer cells compared to their normal counterparts ( Figure 1C ). To assess the generality of these results, we analyzed expression of ferritin H, TfR1, IRP1 and IRP2 in five additional breast cancer cell lines. As shown in Figure 1D , western blot analysis demonstrated a consistent pattern of ferritin H decrease, TfR1 increase, and IRP2 increase in these breast cancer cell lines when compared to normal mammary epithelial cells. In contrast, IRP1 levels were variable. IRP2 mRNA was increased relative to HME cells in all except one cell line (MDA-MB-453), suggesting that both transcriptional and post-transcriptional mechanisms drive the enhanced expression of IRP2 in breast cancer cells (Supplemental Figure   1 ). As anticipated, transcript levels of TfR1 were increased in these breast cancer cell lines. 
Knockdown of IRP2, not IRP1, inhibits cancer cell growth in vitro.
To determine the role of IRP overexpression in breast cancer, we first examined the effect of IRP knockdown on cancer cell growth in vitro. As shown in Figure 3A , knockdown of IRP2 significantly decreased cell growth as measured by a metabolic assay. To confirm that this inhibitory effect is specifically attributable to IRP2 knockdown, a rescue experiment was performed by transfecting IRP2 knockdown cells with an IRP2 expression vector that is not recognized by IRP2 shRNA ( Figure   3B ). After IRP2 protein was restored, the inhibition of cell growth was abolished, and cells grew Figure 2 , IRP2 knockdown increases ferritin, decreases TfR1, and decreases metabolically available iron, creating an iron deficient condition.
IRP2 knockdown induces apoptosis. As shown in
As iron deficiency has previously been shown to trigger apoptosis (41, 42), we examined whether the inhibitory effect of IRP2 knockdown on cell growth is related to apoptosis by measuring the activity of caspase 3/7, proteases that are selectively activated during apoptosis (43) . As shown in Figure 4A , caspase activity was significantly increased after IRP2 knockdown. To confirm these results, we used flow cytometry to assess levels of annexin V as well as uptake of 7-AAD following IRP2 knockdown. Annexin V measures exposure of phosphatidylserine on the cell surface and is a marker of early apoptosis(44), whereas 7-AAD permeability is an indicator of plasma membrane integrity and is associated with late-stage apoptosis (45) . As shown in Figure 4B , both these markers were elevated following IRP2 knockdown. CAN-13-1224 subtypes with significantly different outcomes: normal-like, luminal A (LumA), HER2-enriched, luminal B (LumB), and basal (46) . We analyzed the distributions of IRP2 mRNA levels according to subtype. As shown in Figure 6B , IRP2 mRNA is lower in the normal-like subtype, which has a favorable prognosis, and higher in the LumB and Basal subtypes, which have a poorer prognosis. IRP2 mRNA was also higher in the LumA subtype than in the normallike subtype. Median IRP2 levels were higher in the ERBB2 subtype, although the difference between IRP2 expression in normal-like and ERBB2 subtypes did not attain statistical significance ( Figure 6B ). IRP2 expression was not associated with distant metastasis-free survival (not shown).
To obtain insight into mechanisms responsible for IRP2 reduction in breast tumors, we performed a pathway analysis on a large cohort of 759 breast tumors (25) . We ranked tumors based on IRP2 expression and selected the upper and low deciles (i.e. 76 tumors per group) for analysis of differential expression. We then ranked the genes by false-discovery adjusted pvalue (FDR) and selected the top 1% of probe sets on the array (q<0.001; 448 probe sets) for further analysis. Of these, 369 were overexpressed in the IRP2 overexpressors (IRP2 "high" genes), and 79 were overexpressed in the IRP2 underexpressors (IRP2 "low" genes). We analyzed each group of genes by DAVID pathway analysis (47, 48). The "low" genes showed no enrichment of biological terms after FDR adjustment. By contrast, the "high" genes showed highly significant term enrichment after FDR correction. We examined the Gene Ontology (GO) biological process (GOTERM_BP) terms on this list (Supplemental Table 2 ). The 7 top GO BP categories involved cellular catabolic processes. Although genes in these categories showed some overlap, they included cellular macromolecule catabolic process (p=2.6 x 10 involved in cellular protein catabolic process (p=1.6x10 -5 ), and modification-dependent macromolecule catabolic process (p=2.1x10 -5 ), suggesting that genes involved in protein catabolism, such as ubiquitin-dependent proteolysis, are highly upregulated in the IRP2 overexpressors. Genes involved in protein transport and RNA processing also showed significant enrichment.
Discussion
In this report, we identify IRP2 as an iron regulatory protein upregulated in breast cancer ( Figure   1, 6 ). The increase in IRP2 had functional consequences, leading to an increase in IRE binding activity, which in turn was associated with a decrease in ferritin, an increase in TfR1, and an increase in labile iron (Figure 1,2) . These findings are consistent with the classical function of IRP2 in iron regulation, and suggest that enhanced IRP2 expression in breast cancer increases intracellularly available iron by increasing iron uptake and decreasing iron storage. Taken together with our previous observations that breast cancer cells have diminished expression of the Fe(II) exporter ferroportin (12), our results suggest a model in which decreased iron storage (low ferritin), increased iron uptake (high TfR1), and decreased iron export (low ferroportin) all contribute to supporting high levels of labile iron in breast cancer (Figure 7) . The results presented in this manuscript further suggest that at least in some breast cancers, this pathway may be driven by increased expression of IRP2.
Our studies suggest that IRP2 may be functionally more important than IRP1 in controlling iron The effect of IRP2 overexpression on tumor growth has been studied in lung cancer using a tetoff system to overexpress IRP2 in H1299 lung cancer cells (54) . Consistent with our observations, overexpression of IRP2 stimulated tumor growth when H1299 cells were injected subcutaneously in nude mice. However, in contrast to our observations, only a slight increase in TfR1 expression, and no change in ferritin H expression was observed, leading to the suggestion that the tumorigenic properties of IRP2 may not depend on its classic iron regulatory function (54) . In contrast, our results suggest that changes in expression of IRP2 are associated with changes in levels of the classic IRP2 targets TfR1 and ferritin. Differences between the two studies may be attributable to the different cancers investigated (lung vs breast), or to differences in experimental design (overexpression vs knockdown in the current report). It is also possible that chronic overexpression may engender an adaptive response enabling ferritin to escape IRP2 regulation, or that IRP2 levels may already be saturating in cancer cells, such that further upregulation does not lead to an incremental repression of ferritin.
To explore the relevance of these findings to human breast cancer, we examined the association between IRP2 expression and tumor grade using expression microarray data from a cohort study 
We also assessed the expression of IRP2 in molecular subtypes of breast cancer. Breast cancer is a heterogeneous disease, comprising several subtypes that differ considerably in prognosis (46) . Recent work has shown that these can be divided according to molecular profile into intrinsic subtypes termed normal-like, luminal A (LumA), luminal B (LumB), ERBB2, and basal (55).
We observed that when compared to the normal-like subtype, IRP2 is upregulated in LumA, LumB and basal subtypes, but not in the ERBB2 subtype ( Figure 6 ) (which comprises approximately 20% of all breast cancers (56)). In contrast, we previously observed that ferroportin is downregulated in all breast cancer molecular subtypes (12) . Thus, upregulation of IRP2 may drive changes in ferroportin and iron metabolism in some but not all breast cancers.
This interpretation is in line with our recent work demonstrating that there are multiple pathways through which breast tumors modulate expression of 'iron genes' to acquire and retain more iron (25) . For example, we previously reported that two separate gene dyads were particularly important in determining patient outcome: TfR1 and HFE (which control iron import), and ferroportin and hepcidin (which control iron export). Patients with a good prognosis frequently exhibited either a favorable iron import or iron export prognosis profile, but not both (25) .
Our analysis did not demonstrate an association of IRP2 expression with distant metastasis-free survival, perhaps suggesting that IRP2 is important in tumor cell growth but does not influence processes involved in metastasis, such as migration and invasion. Alternatively, effects of IRP2 on metastasis-free survival may only become apparent when expression of another gene is simultaneously affected. For example, we previously demonstrated that expression of hepcidin is only correlated with survival in patients with tumors that express elevated levels of ferroportin; in tumors with low levels of ferroportin, expression of hepcidin did not affect DMFS (25) . 
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